Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pregnancy Immune Function Clear all
Recruiting Phase 1 Interventional

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

NCT06623630
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

NCT01575925
View directory record Official record
Conditions
Multiple Myeloma, Renal Impairment
Interventions
4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional MRI in Lupus Nephritis

NCT01731054
View directory record Official record
Conditions
Healthy, Lupus Nephritis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Los Angelos, California • Torrance, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

NCT00810329
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Multiple Chemical Sensitivity, Interstitial Cystitis, Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting No phase listed Observational

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up

NCT06106646
View directory record Official record
Conditions
Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
Interventions
No active intervention in this protocol (previously randomized to Vitamin C), No active intervention in this protocol (previously randomized to Placebo)
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 16 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626
View directory record Official record
Conditions
MDS, AML, Solid Tumors, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Berkeley, California • Hialeah, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational

Vitamin C Supplementation to Pregnant Smokers: Follow-up of 2 Randomized Trials Plus Changes in DNA Methylation

NCT03206710
View directory record Official record
Conditions
Asthma, Wheezing, In Utero Nicotine, Pulmonary Function
Interventions
No current intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Months to 11 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NCT06855706
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
Behavioral · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational

Impact of Respiratory Pathogens in Infants

NCT01789268
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Respiratory Inductive Plethysmography
Device
Lead sponsor
University of Rochester
Other
Eligibility
0 Days to 3 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 11, 2026, 11:43 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Oxalate and Immune Cell Function

NCT03877276
View directory record Official record
Conditions
Kidney Stone
Interventions
Breakfast, Spinach smoothie, Kale smoothie, Blended smoothie, V spinach smoothie, Sodium oxalate drink
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845
View directory record Official record
Conditions
Primary Immunoglobulin A Nephropathy (IgAN)
Interventions
iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Madera, California • Aurora, Colorado • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

NCT04578834
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 11, 2026, 11:43 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting No phase listed Observational

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

NCT06527872
View directory record Official record
Conditions
Lupus Nephritis
Interventions
None (Observational study)
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Metabolic Effects of Paricalcitol

NCT01003275
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational

Preserving Kidney Function in Children With Chronic Kidney Disease

NCT05169411
View directory record Official record
Conditions
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions
Blood pressure, Urine protein
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
20,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Drug · Combination Product
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Phase 4 Interventional

The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.

NCT00749736
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
cholecalciferol, doxercalciferol, placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 11, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

NCT06797518
View directory record Official record
Conditions
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 11, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Impact of an Orthotic Intervention in Children With Peripheral Neuropathy

NCT03655587
View directory record Official record
Conditions
Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy, Acute Lymphocytic Leukemia, Pediatric, Rhabdomyosarcoma, Wilms Tumor
Interventions
Solid ankle foot orthotic, Resting night splint
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 11, 2026, 11:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Tolerance Dysfunction in Pregnancy Due to Ambient Air Pollution Exposure

NCT04549142
View directory record Official record
Conditions
Air Pollution, Pregnancy
Interventions
There is no intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 11, 2026, 11:43 AM EDT